Bafna Pharmaceuticals Limited

NSE BAFNAPH.NS

Bafna Pharmaceuticals Limited Free Cash Flow Yield on February 07, 2025: -3.51%

Bafna Pharmaceuticals Limited Free Cash Flow Yield is -3.51% on February 07, 2025, a -164.53% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Bafna Pharmaceuticals Limited 52-week high Free Cash Flow Yield is -1.32% on February 08, 2024, which is 62.40% above the current Free Cash Flow Yield.
Bafna Pharmaceuticals Limited 52-week low Free Cash Flow Yield is -3.61% on February 05, 2025, which is -2.79% below the current Free Cash Flow Yield.
Bafna Pharmaceuticals Limited average Free Cash Flow Yield for the last 52 weeks is -2.89%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NSE: BAFNAPH.NS

Bafna Pharmaceuticals Limited

CEO	Mr. Bansilal Mahaveer Chand Bafna
IPO Date	Nov. 12, 2012
Location	India
Headquarters	Bafna Towers
Employees	363
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Cleaning Supplies Composite Materials Cosmetics Drugstores & Retail Pharmacies Glass Plastics

Description

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.

Key trends

Past 5 years